A detailed history of Nebula Research & Development LLC transactions in Guardant Health, Inc. stock. As of the latest transaction made, Nebula Research & Development LLC holds 38,361 shares of GH stock, worth $1.25 Million. This represents 0.11% of its overall portfolio holdings.

Number of Shares
38,361
Holding current value
$1.25 Million
% of portfolio
0.11%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$22.3 - $36.29 $855,450 - $1.39 Million
38,361 New
38,361 $880 Million
Q1 2024

May 15, 2024

BUY
$17.13 - $26.91 $860,868 - $1.35 Million
50,255 Added 250.36%
70,328 $1.45 Billion
Q4 2023

Feb 14, 2024

BUY
$21.58 - $29.5 $122,962 - $168,091
5,698 Added 39.64%
20,073 $543 Million
Q3 2023

Nov 14, 2023

BUY
$25.8 - $39.97 $370,875 - $574,568
14,375 New
14,375 $426 Million
Q1 2023

May 15, 2023

BUY
$22.92 - $33.76 $311,116 - $458,258
13,574 New
13,574 $318 Million

Others Institutions Holding GH

About Guardant Health, Inc.


  • Ticker GH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 102,220,000
  • Market Cap $3.34B
  • Description
  • Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...
More about GH
Track This Portfolio

Track Nebula Research & Development LLC Portfolio

Follow Nebula Research & Development LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nebula Research & Development LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nebula Research & Development LLC with notifications on news.